Published in Clin Cancer Res on April 15, 2005
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
MuSiC: identifying mutational significance in cancer genomes. Genome Res (2012) 4.73
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99
Class I PI3K in oncogenic cellular transformation. Oncogene (2008) 3.90
PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A (2008) 3.87
Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer (2009) 3.46
Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A (2007) 3.15
Mutation of the PIK3CA oncogene in human cancers. Br J Cancer (2006) 3.04
Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell (2008) 3.02
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther (2011) 1.98
PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 1.90
Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J (2007) 1.74
Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions. Cancer Cell (2013) 1.74
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2005) 1.73
Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS One (2007) 1.56
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle (2009) 1.54
Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J Cancer (2005) 1.48
Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study. Gynecol Oncol (2010) 1.47
Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer (2008) 1.42
Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle (2008) 1.35
The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics (2007) 1.33
A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Res Notes (2009) 1.29
Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol (2010) 1.27
ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res (2011) 1.23
Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle (2010) 1.22
Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet A (2014) 1.20
KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS One (2012) 1.14
ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci (2013) 1.14
Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Hugo J (2011) 1.13
PIK3CA alterations in Middle Eastern ovarian cancers. Mol Cancer (2009) 1.11
EGF-induced activation of Akt results in mTOR-dependent p70S6 kinase phosphorylation and inhibition of HC11 cell lactogenic differentiation. BMC Cell Biol (2006) 1.11
ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system. Acta Pharmacol Sin (2010) 1.08
mTOR signaling in tumorigenesis. Biochim Biophys Acta (2014) 1.06
Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas. Virchows Arch (2008) 1.05
Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J Cell Biochem (2008) 1.04
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res (2008) 1.02
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol Cancer Ther (2012) 1.01
Up-regulation of PIK3CA promotes metastasis in gastric carcinoma. World J Gastroenterol (2010) 1.00
Molecular-targeted therapies for ovarian cancer: prospects for the future. Int J Clin Oncol (2012) 0.99
Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry. Proc Natl Acad Sci U S A (2006) 0.98
Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation. PLoS One (2009) 0.97
Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res (2011) 0.97
Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol (2014) 0.96
Major clinical research advances in gynecologic cancer in 2012. J Gynecol Oncol (2013) 0.96
Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers. Breast Cancer Res (2010) 0.96
Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken) (2010) 0.95
The role of activin A and Akt/GSK signaling in ovarian tumor biology. Endocrinology (2008) 0.94
Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am (2013) 0.94
Combining targeted therapies: practical issues to consider at the bench and bedside. Oncologist (2010) 0.94
Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Res (2011) 0.93
Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma. BMC Cancer (2012) 0.93
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. Clin Cancer Res (2014) 0.92
Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead. Adv Exp Med Biol (2008) 0.92
RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway. Oncotarget (2015) 0.92
E17K substitution in AKT1 in prostate cancer. Br J Cancer (2010) 0.91
t-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer. Mol Cancer (2010) 0.90
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review). Int J Oncol (2015) 0.90
Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. J Cell Mol Med (2013) 0.90
Aquaporin-3 positively regulates matrix metalloproteinases via PI3K/AKT signal pathway in human gastric carcinoma SGC7901 cells. J Exp Clin Cancer Res (2011) 0.89
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition. Breast Cancer Res (2014) 0.88
Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment. PLoS One (2008) 0.88
Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 0.87
Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R. Oncogenesis (2013) 0.87
PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients. Acta Pharmacol Sin (2013) 0.86
The PIK3CA gene as a mutated target for cancer therapy. Curr Cancer Drug Targets (2008) 0.86
PIK3CA mutations in ovarian cancer. Clin Cancer Res (2005) 0.86
Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity. Gynecol Oncol (2012) 0.86
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Oral Oncol (2015) 0.85
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer (2013) 0.84
In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA. Invest New Drugs (2014) 0.84
New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. Biomed Res Int (2013) 0.84
Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells. Gynecol Oncol (2009) 0.84
Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects. Biophys Rev (2014) 0.84
Artemether combined with shRNA interference of vascular cell adhesion molecule-1 significantly inhibited the malignant biological behavior of human glioma cells. PLoS One (2013) 0.83
Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers. Apoptosis (2013) 0.83
Aberrant expression of LMO4 induces centrosome amplification and mitotic spindle abnormalities in breast cancer cells. J Pathol (2010) 0.83
Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget (2016) 0.83
Targeting the PI3K pathway for cancer therapy. Future Med Chem (2012) 0.82
Activation of the MEK-S6 pathway in high-grade ovarian cancers. Appl Immunohistochem Mol Morphol (2010) 0.82
Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy. Jpn J Clin Oncol (2015) 0.82
PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer. Breast Cancer Res (2013) 0.82
Cancer gene discovery in mouse and man. Biochim Biophys Acta (2009) 0.81
The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. Mol Cancer Ther (2013) 0.81
Antineoplastic effects of mammalian target of rapamycine inhibitors. World J Transplant (2012) 0.80
Arab gene geography: From population diversities to personalized medical genomics. Glob Cardiol Sci Pract (2014) 0.80
Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes. Clinics (Sao Paulo) (2011) 0.79
Structural basis of nSH2 regulation and lipid binding in PI3Kα. Oncotarget (2014) 0.79
Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness. Virchows Arch (2016) 0.78
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer. Clin Cancer Res (2014) 0.78
Anti-Tumor Effects of Atractylenolide-I on Human Ovarian Cancer Cells. Med Sci Monit (2017) 0.78
Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy. Toxicol Pathol (2013) 0.78
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. Oncotarget (2016) 0.77
Evaluation of expression of the PTEN gene, oestrogen and progesterone receptors as diagnostic and predictive factors in endometrial cancer. Pathol Oncol Res (2013) 0.77
HS-133, a novel fluorescent phosphatidylinositol 3-kinase inhibitor as a potential imaging and anticancer agent for targeted therapy. Oncotarget (2014) 0.76
Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer. J Gastric Cancer (2016) 0.75
Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity. MAbs (2016) 0.75
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2002) 7.84
Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol (2002) 6.51
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol (2003) 5.20
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A (2008) 4.76
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res (2008) 4.05
Accidental hypothermia. N Engl J Med (2012) 4.01
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst (2002) 3.40
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol (2004) 2.91
Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am (2003) 2.82
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol (2002) 2.80
Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res (2005) 2.72
A FoxO-Smad synexpression group in human keratinocytes. Proc Natl Acad Sci U S A (2006) 2.60
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol (2009) 2.45
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol (2007) 2.19
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res (2002) 2.16
The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. Gynecol Oncol (2008) 2.14
Update on the indications for nipple-sparing mastectomy. J Support Oncol (2006) 2.13
Incidence of venous thromboembolism after minimally invasive surgery in patients with newly diagnosed endometrial cancer. Obstet Gynecol (2012) 2.09
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res (2003) 2.09
BLM heterozygosity and the risk of colorectal cancer. Science (2002) 2.03
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer (2006) 2.03
The accuracy of sentinel lymph node biopsy in multicentric and multifocal invasive breast cancers. J Am Coll Surg (2003) 1.88
The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg (2004) 1.87
Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res (2005) 1.86
Implication of snoRNA U50 in human breast cancer. J Genet Genomics (2009) 1.80
Clinicopathologic features of rhabdomyosarcoma of gynecologic origin in adults. Am J Surg Pathol (2007) 1.79
Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy? J Am Coll Surg (2005) 1.77
Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys (2005) 1.77
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol (2008) 1.75
Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: biologic metastasis or procedural artifact? Cancer (2004) 1.74
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol (2003) 1.74
Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature. Gynecol Oncol (2006) 1.73
Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer (2013) 1.71
Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma : a Gynecologic Oncology Group study. Cancer (2006) 1.71
Subcutaneous tumor implantation after laparoscopic procedures in women with malignant disease. Obstet Gynecol (2004) 1.69
Eighteen sensations after breast cancer surgery: a 5-year comparison of sentinel lymph node biopsy and axillary lymph node dissection. Ann Surg Oncol (2007) 1.66
Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol (2005) 1.64
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol (2006) 1.64
Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol (2007) 1.63
Comparison of avalanche survival patterns in Canada and Switzerland. CMAJ (2011) 1.62
Molecular profiling of endometrial cancers from African-American and Caucasian women. Gynecol Oncol (2005) 1.62
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol (2004) 1.60
The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered? Int J Gynecol Cancer (2011) 1.60
Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence. Ann Surg Oncol (2007) 1.60
Nipple-sparing mastectomy for breast cancer and risk reduction: oncologic or technical problem? J Am Coll Surg (2006) 1.56
Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res (2003) 1.56
Pelvic exenteration with curative intent for recurrent uterine malignancies. Gynecol Oncol (2011) 1.55
Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol (2007) 1.54
Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping. BMC Genet (2008) 1.53
The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol (2012) 1.52
The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol (2006) 1.51
Can sentinel lymph node biopsy be omitted in patients with favorable breast cancer histology? Ann Surg Oncol (2004) 1.48
Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer. Gynecol Oncol (2012) 1.47
Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res (2005) 1.46
Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat (2002) 1.44
Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature. Gynecol Oncol (2007) 1.44
Pilot study prospectively evaluating the use of the measurement of preoperative sonographic endometrial thickness in postmenopausal patients with endometrial cancer. Menopause (2005) 1.43
Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol (2003) 1.43
Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol (2010) 1.42
The role of the breast cancer surgeon in personalized cancer care: clinical utility of the 21-gene assay. Am J Surg (2012) 1.40
Ureteroileocecal appendicostomy based urinary reservoir in irradiated and nonirradiated patients. J Urol (2009) 1.38
The importance of local control in early-stage breast cancer: a historical review and a discussion of ongoing issues. Ann Surg Oncol (2007) 1.38
The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol (2010) 1.37
Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? Gynecol Oncol (2009) 1.35
The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecol Oncol (2009) 1.33
Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer (2009) 1.32
Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth Analg (2002) 1.32
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer (2011) 1.32
Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol (2005) 1.32
The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol (2007) 1.28
CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol (2006) 1.28
Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. J Clin Oncol (2009) 1.27
Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol (2004) 1.27
Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer (2003) 1.27
Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One (2010) 1.25
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res (2008) 1.25